The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients.
It is a copyrighted instrument, which has been translated and validated into 81 languages and is used in more than 3,000 studies worldwide. Presently QLQ-C30 Version 3.0 is the most recent version and should be used for all new studies.
It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
We have also developed a Satisfaction with Care measure (EORTC-IN-PATSAT32) and a Palliative Care questionnaire (QLQ-C15-PAL). These are also general questionnaires.
Conditions for its use are dependent on whether it will be employed in an academic or commercial setting. For academic settings, there is no charge, but a User's agreement is required for each study (please go to 'Downloads' to fill in a download request).
The download request on this website is for academic use only
For studies carried out on behalf of a commercial sponsor or if your study is being partially sponsored by the pharmaceutical industry, a compensation fee is payable. A compensation fee is required per study. The amount of the fee depends on the number of patients. For further details for commercial use, please contact Julie Walker directly.
Thank you for your understanding
The funds that are generated through the copyright arrangement are used exclusively to support the on-going research of the QLG on the development and refinement of quality of life instruments.
Contact us for further information for academic studies and for commercial studies.
A new version of the QLQ-C30 based on computer-adaptive testing is being developed. For more information, click here.
Can I see a copy of the EORTC QLQ-C30?
A specimen of the EORTC QLQ-C30 is available by clicking here.